Evidence method
Level · gp.fundamentals.debt_to_revenue
315.10% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
TCRX · Dec 31, 2025
TScan Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-26-089884General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
42.68% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-1310.60% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
266.65% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-1315.38% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
1105.57% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
113.38% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History11 statesHistory building
Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 1290.88%
- Current
- 315.10%
- Delta
- -975.78%
- Previous
- 56.75%
- Current
- 42.68%
- Delta
- -14.07%
- Previous
- -1292.87%
- Current
- -1310.60%
- Delta
- -17.72%
- Previous
- 139.37%
- Current
- 266.65%
- Delta
- 127.28%
- Previous
- -1475.59%
- Current
- -1315.38%
- Delta
- 160.21%
- Previous
- 1262.01%
- Current
- 1105.57%
- Delta
- -156.44%
- Previous
- 119.91%
- Current
- 113.38%
- Delta
- -6.54%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · TCRX Fundamental State →Has State · TScan Therapeutics, Inc. →Transitioned To · TCRX Fundamental State →Transitioned To · TCRX BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · TCRX CAPEX_INTENSITY_DECREASED →Transitioned To · TCRX CASH_GENERATION_DECREASED →Transitioned To · TCRX GROWTH_INCREASED →Transitioned To · TCRX PROFITABILITY_INCREASED →Transitioned To · TCRX R_AND_D_INTENSITY_DECREASED →Transitioned To · TCRX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.